Bragar Eagel & Squire, P.C. has launched an investigation into HCA Healthcare, Inc. on behalf of its stockholders. The investigation concerns whether HCA violated federal securities laws or engaged in other unlawful business practices. The inquiry follows HCA's July 14, 2026 announcement of preliminary second-quarter 2026 results, in which the company sharply lowered its full-2026 profit guidance, citing an unfavorable shift in payer mix that impacted revenue by approximately $400 million in the quarter. On that news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share. The law firm encourages investors who purchased or acquired HCA shares and suffered a loss to contact partners Brandon Walker or Melissa Fortunato to discuss their legal rights.
HCA Healthcare, Inc.HCA lowered full-year profit guidance and reported unfavorable payer mix, causing a 6.95% stock drop.